NCT07480720 Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
| NCT ID | NCT07480720 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Elazıg Fethi Sekin Sehir Hastanesi |
| Condition | Graves Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2026-03-01 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years Diagnosis of Graves' disease (for the patient group) No known thyroid disease in healthy control participants Availability of optical coherence tomography (OCT) measurements and laboratory data Time interval between OCT examination and blood sampling ≤ 10 days Exclusion Criteria: * Presence of glaucoma, optic neuropathy, or retinal vascular diseases Macular diseases, uveitis, or severe refractive error (high myopia \>6 diopters) Diabetic retinopathy History of previous intraocular surgery History of active infection, malignancy, or systemic inflammatory disease Poor-quality OCT measurements (segmentation errors or low signal strength)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07480720 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Graves Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07480720 currently recruiting?
Yes, NCT07480720 is actively recruiting participants. Contact the research team at kesersinem@hotmail.com for enrollment information.
Where is the NCT07480720 trial being conducted?
This trial is being conducted at Elâzığ, Turkey (Türkiye).
Who is sponsoring the NCT07480720 clinical trial?
NCT07480720 is sponsored by Elazıg Fethi Sekin Sehir Hastanesi. The trial plans to enroll 100 participants.